AstronauTx
June 24, 2026
Theater 4
Type: Company Presentation
Focus Area:
Brain Health
AstronauTx’s is targeting sleep architecture as a therapeutic approach to treat neurological disease. Our thesis is that changes in sleep architecture underpin disease and that sleep is a modifiable risk factor for chronic neurodegeneration. By improving slow wave sleep quality, we aim to slow cognitive decline associated with aging and dementia. Our approach is grounded in a combination of well-defined, quantifiable biological endpoints, such as EEG-based sleep architecture metrics and measurable improvements in cognitive function and glymphatic flow.
Founded by SV Health’s Dementia Discovery Fund, AstronauTx completed a £48 million/$61 million Series A financing in October 2023, led by the Novartis Venture Fund, with participation from SV’s Dementia Discovery Fund, MPM BioImpact, Brandon Capital, EQT Life Sciences and Bristol Myers Squibb.
Company HQ City:
London
Company HQ State:
UK
Company HQ Country:
United Kingdom
Year Founded:
2019
Lead Product in Development:
Novel treatment for early Alzheimer’s disease
CEO
Dr. Jane Rhodes, PhD, MBA
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
2
When you expect your next catalyst update?
November 2026
What is your next catalyst (value inflection) update?
Development candidate nominated and next catalyst is IND/regulatory filing
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}